Search
Tag: Grifols
Reversing age: dual species measurement of epigenetic age with a single clock
This study explores the effects of young blood plasma on aging at the epigenetic level in rats, specifically examining whether plasma treatment can alter…
Read More
Old plasma dilution reduces human biological age: a clinical study
This study extends findings from animal research on blood heterochronicity to humans, introducing a direct measure of biological age based on changes in 10…
Read More
Complementary analyses of the AMBAR trial: Impact of discontinuations, consistency of results across outcomes and additional adjustments
The AMBAR study analyzed the effects of plasma exchange (PE) with albumin (with or without intravenous immunoglobulin, IVIG) on mild-to-moderate Alzheimer’s disease (AD) patients….
Read More
Plasma Replacement Shows Success in Mild to Moderate Alzheimer Disease
TThe AMBAR (Alzheimer Management by Albumin Replacement) study by Grifols demonstrated that plasma exchange (PE) with albumin and immunoglobulin replacement could delay cognitive and…
Read More
Perspective: Is therapeutic plasma exchange a viable option for treating Alzheimer’s disease?
Therapeutic plasma exchange (TPE) is being explored as a treatment for Alzheimer’s disease (AD) to remove toxic or aging-related factors from the blood. Preclinical…
Read More
Emerging insights into the role of albumin with plasma exchange in Alzheimer’s disease management
Alzheimer’s disease (AD) is a neurodegenerative condition marked by cognitive decline and eventually death. The main pathological features of AD include amyloid-β (Aβ) plaques…
Read More
Longitudinal lipidomic analyses in patients undergoing therapeutic plasma exchange with albumin replacement as a treatment for Alzheimer’s disease
This study from the AMBAR trial investigated the effects of plasma exchange with albumin replacement (PE-Alb) on lipidomic profiles in patients with mild-to-moderate Alzheimer’s…
Read More
Feasibility, safety, and tolerability of two modalities of plasma exchange with albumin replacement to treat elderly patients with Alzheimer’s disease in the AMBAR study
The AMBAR study examined the feasibility and safety of plasma exchange (PE) with albumin replacement in patients with mild-to-moderate Alzheimer’s disease (AD). Patients received…
Read More
Inflammatory biomarkers in patients undergoing therapeutic plasma exchange with albumin replacement as a treatment for Alzheimer’s disease
TThis study from the AMBAR (Alzheimer Management by Albumin Replacement) phase 2b/3 trial examined the effects of plasma exchange with albumin replacement (PE-Alb) on…
Read More
Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild‑to‑moderate Alzheimer’s disease: additional results from the AMBAR study
This study, part of the AMBAR phase 2b/3 clinical trial, investigated structural and functional brain changes in Alzheimer’s disease (AD) patients treated with therapeutic…
Read More
P57 Mapping Quality of Life – Alzheimer’s Disease (QOL-AD) Scores to EQ-5D-5L Utilities in the Ambar Trial Population
The AMBAR trial assessed the health-related quality of life (HRQoL) impact of plasma exchange with albumin replacement in mild-to-moderate Alzheimer’s disease (AD) patients. Using…
Read More
Impact of therapeutic and low volume plasma exchange on clinical laboratory parameters in patients treated for Alzheimer’s disease from the AMBAR study
The AMBAR trial studied the effects of plasma exchange (PE) on clinical laboratory parameters in Alzheimer’s disease (AD) patients. In this trial, 322 AD…
Read More